The availability of target treatments and HER2-directed HER2 antibodies such as: lapatinib, neratinib, trastuzumab, pertuzumab, trastuzumab emtansine (T-DM1) and recently trastuzumab deruxtecan, among others have significantly increased the survival of patients with HER2-positive early and advanced stage breast cancer [2]. The gene discussed is ERBB2; the disease is breast carcinoma.